Jazz Presents Overall Survival & Longer Data From Trial Of Zanidatamab In Biliary Tract Cancer

(RTTNews) - Jazz Pharmaceuticals plc (JAZZ) announced long-term follow-up results, including the first-ever overall survival or OS findings, from the Phase 2b HERIZON-BTC-01 clinical trial of zanidatamab in previously treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer or BTC.

The company noted that Zanidatamab demonstrated a median overall survival (OS) of 15.5 months in patients with centrally confirmed immunohistochemistry (IHC) 2+ or 3+ and a median OS of 18.1 months in patients with IHC 3+ tumors.

The median duration of response (DoR), one of the trial's key secondary endpoints, increased by approximately 2 months to 14.9 months, compared to the previously reported findings. In the data cut, zanidatamab demonstrated a median estimated OS, another secondary endpoint, of 15.5 months in all patients with HER2+ BTC, 18.1 months in patients with IHC 3+ tumors, and 5.2 months in patients with IHC 2+ tumors. Results highlight the clinically meaningful benefits of sustained and durable responses with continued treatment with zanidatamab.

For More Such Health News, visit rttnews.com.